These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38867860)

  • 1. Lipid-lowering approaches to manage statin-intolerant patients.
    Ruscica M; Bertoletti A; Gobbi C; Sirtori CR; Carugo S; Corsini A
    Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i56-i59. PubMed ID: 38867860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice.
    Bosco G; Di Giacomo Barbagallo F; Spampinato S; Lanzafame L; Di Pino A; Piro S; Purrello F; Scicali R
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
    Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
    Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
    Moriarty PM; Jacobson TA; Bruckert E; Thompson PD; Guyton JR; Baccara-Dinet MT; Gipe D
    J Clin Lipidol; 2014; 8(6):554-561. PubMed ID: 25499937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
    Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid for the treatment of dyslipidemia.
    Marrs JC; Anderson SL
    Drugs Context; 2020; 9():. PubMed ID: 32922503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-Lowering Therapy after Acute Coronary Syndrome.
    Pogran E; Burger AL; Zweiker D; Kaufmann CC; Muthspiel M; Rega-Kaun G; Wenkstetten-Holub A; Wojta J; Drexel H; Huber K
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance.
    Voutyritsa E; Damaskos C; Farmaki P; Kyriakos G; Diamantis E; Quiles-SÁnchez LV; Garmpi A; Garmpis N; Patsouras A; Stelianidi A; Savvanis S
    In Vivo; 2021; 35(1):61-68. PubMed ID: 33402450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.